QureBio Ltd. Showcases Promising Results for Q-1802
QureBio Ltd., a forward-thinking clinical-stage biotech company, is gaining attention for its innovative approach to treating challenging medical conditions. Focusing on the development of bispecific antibodies and enhanced biopharmaceuticals, the company has recently shared findings from its Q-1802 program at the prestigious ASCO event. This announcement has sparked excitement in the medical and biopharmaceutical communities.
Exciting Findings From the ASCO Abstract Submission
At the latest ASCO meeting, QureBio Ltd. presented an abstract detailing the Phase Ib/II clinical data for its Q-1802 therapeutic program. The study, titled "Phase?/? Trial of Anti-CLDN18.2/PD-L1 Recombinant Humanized Bispecific Antibody Q-1802 Plus XELOX in Treatment-Naive CLDN18.2-Positive Advanced GC/GEJ," highlights the progress made in this important area of cancer therapeutics.
Study Overview and Patient Enrollment
The clinical trial involved 62 eligible patients suffering from CLDN18.2-positive and HER2-negative advanced gastric cancer (GC) or gastroesophageal junction (GEJ) tumors. These individuals had not received any prior treatments and were histologically confirmed to have unresectable locally advanced or metastatic disease. Participants were administered Q-1802 in conjunction with the standard XELOX chemotherapy regimen at varying doses of 10 mg/kg or 20 mg/kg every two weeks.
Safety Profile and Adverse Events
Throughout the study, no dose-limiting toxicities (DLTs) were reported, and the maximum tolerated dose (MTD) was not reached. The most commonly observed grade 3 adverse events (AEs) related to Q-1802 included thrombocytopenia at 8.1% and neutropenia at 6.5%, alongside other conditions like anemia and hypokalemia, which occurred at 4.8% each. Importantly, the discontinuation of treatment due to AEs was minimal at 6.5%, and there were no treatment-related fatalities.
Notable Efficacy Data
Among the 60 patients who could be evaluated for efficacy, the overall response rate (ORR) was found to be 70.0%, with a disease control rate (DCR) of 98.3%. The duration of progression-free survival (mPFS) averaged 11.3 months. In the cohort receiving 10 mg/kg of Q-1802, the ORR increased to 73.0%, with a notable 81.8% in patients who exhibited high expression of CLDN18.2 alongside a PD-L1 combined positive score (CPS) of 5 or higher, with an extended mPFS observed at 12.2 months.
Conclusion and Future Directions
Dr. Gong and the study authors heralded the combination of Q-1802 with XELOX as a regimen with manageable safety parameters and promising antitumoral effects, which advocate for the initiation of a phase III trial. Recent approvals by regulatory authorities have paved the way for further exploration with Q-1802 at a recommended dose of 10 mg/kg.
Understanding the Q-1802 Therapy
Q-1802 is a cutting-edge humanized bispecific antibody, targeting both Claudin18.2 and PD-L1, and designed to enhance tumor destruction through both innate and adaptive immune mechanisms. Its unique ability to stimulate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) offers a significant advancement in treatment options for those diagnosed with Claudin18.2 positive tumors.
About QureBio Ltd.
Established in 2017, QureBio Ltd. is dedicated to addressing urgent clinical needs through innovative biopharmaceutical advancements, especially in treating refractory cancers and inflammation. The talented team of scientists behind QureBio has developed proprietary technologies focused on engineered bio-macromolecules, including groundbreaking platforms for bispecific and tri-specific antibodies.
The company has successfully secured funding from various esteemed investors, enabling it to forge partnerships and collaborations aimed at tackling unmet medical needs. QureBio continues to work alongside industry leaders to develop novel therapeutic solutions that promise to enhance patient outcomes.
Contact Information
If you have any inquiries or require further information about QureBio Ltd. and its innovative projects, you can reach them at:
Telephone: +86 21-50920280
Email: [Contact Email Redacted]
Website: www.qurebio.com
Address: 1227 Zhangheng Road, Building 1st, Room 206, Pudong New Area, Shanghai, Postal Code: 201203
Frequently Asked Questions
What is Q-1802?
Q-1802 is a bispecific antibody designed to target Claudin18.2 and PD-L1, aimed at treating advanced cancers.
What were the key findings of the Phase II trial?
The trial showed a 70% overall response rate and a very low treatment discontinuation rate, suggesting promising efficacy and manageable safety.
What are the side effects associated with Q-1802?
Common side effects included thrombocytopenia, neutropenia, and anemia, but serious adverse events were rare.
What is the future for Q-1802?
A phase III trial has been approved, paving the way for further research on Q-1802's effectiveness in treating advanced cancer.
Who can benefit from Q-1802?
Patients with CLDN18.2-positive and HER2-negative advanced gastric cancer may benefit from Q-1802 therapy.
